Hims and Hers Health Inc vs iShares Core S&P 500 ETF — how do they compare? Hims and Hers Health Inc trades at $30.83 (market cap $6.55B), while iShares Core S&P 500 ETF trades at $782.43 (market cap $897.20B). The key difference: iShares Core S&P 500 ETF is far larger — about 137× Hims and Hers Health Inc's market cap, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and iShares Core S&P 500 ETF for 46 Days on average.
| HIMS | IVV | |
|---|---|---|
Market Cap | $6.55B | $897.20B |
Volume | 14,842,814 | 4,580,672 |
Sector | Health | Broad Market / Factor |
52-Week High | $62.76 | $782.58 |
52-Week Low | $14.52 | $634.93 |
Typical Hold Time | 21 Days | 46 Days |
Enterprise Value | $7.25B | — |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.
The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.
IVV, tracking the S&P 500, trades at $782.06, up 0.19% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 68.88 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation debates, with earnings growth expected to slow from 35% in 2026 to 15% in 2027 according to Wall Street analysts (24/7 Wall Street, 2026-10-03).
The outlook remains cautiously optimistic with seasonal patterns favoring year-end rallies, though concentration risks in top holdings and slowing profit growth present headwinds. Key support at $775 and resistance at $780 will dictate near-term direction as investors monitor economic data and Federal Reserve policy.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →